Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study.
Carlos A FierroMichal SarneckiJoachim DouaBart SpiessensOscar GoTodd A DaviesGermie van den DobbelsteenJan PoolmanDarren AbbanatWouter HaazenPublished in: Open forum infectious diseases (2023)
ExPEC10V was well tolerated and immunogenic in elderly adults against all but serotype O8.